Splash Beverage Group Acquires Exclusive Global Rights to CannEpil®, an Epilepsy Therapy with Established European Patient Access, FDA Engagement and U.S. Development Potential
Splash Beverage Group has entered into an exclusive global licensing agreement for CannEpil®, a cannabinoid-based investigational therapy for drug-resistant epilepsy that is already prescribed in several international markets and supported by established reimbursement. The acquisition includes rights for global commercialization, including the U.S.…